Pittsburgh, PA--Hemp Synergistics announced a collaboration with Rinus Beintema, a prominent European medical cannabis proponent, to deliver hemp-infused treatments for related symptoms.
Hemp Synergistics has been working hand in hand with well-known cannabis legalization advocate Rinus Beintema and his non-profit group Suver Nuver to develop condition-specific custom-cannabinoid treatments as a user-friendly successor to cannabis oil.
The maximum THC percentage for CBD products is 0.05 percent in the Netherlands, considerably lower than the 0.2 percent found in the rest of Europe. Beintema needed an end-product guaranteed to maintain legal compliance and set out to find an advanced laboratory and manufacturer to assist.
The company announced in a press release that it had already conquered absorption of these substances, referred to as "bioavailability", by preventing the body from breaking them down in the digestive process. This solves the problem by encapsulating the active hemp molecules by utilizing a patent-pending process and product known as Bio-Dri™, which causes a "Trojan Horse Effect" allowing the body to pass these substances by protecting the active ingredients from destructive enzymes to provide an outstanding absorption rate.
Hemp Synergistics went to work in their laboratory to reproduce the cannabis oil formulas of Suver Nuver as precisely as possible in powder form using industrial hemp and created a final product guaranteed to stay within performance metrics specifying no more than 0.05% THC.
Soaring patient-satisfaction rates proved the success of this new powder. Clinical trials were conducted with 300 volunteers, with 82% reporting the same or better effects from the new solution than the oil-based product, an amazing result considering the hefty reduction in the amount consumed.
Suver Nuver has since expanded their clinical trials to over 30,000 patients. This will be followed by a full-country roll-out in the Netherlands in Q3 and expansion into Germany in Q4.
Read more in the press release.